WILLIAM WONG to Hepacivirus
This is a "connection" page, showing publications WILLIAM WONG has written about Hepacivirus.
Connection Strength
1.521
-
A province-by-province cost-effectiveness analysis and budget impact analysis of one-time birth cohort screening of hepatitis C virus (HCV) infection in Canada. Sci Rep. 2023 08 18; 13(1):13484.
Score: 0.732
-
Health care costs associated with hepatitis C virus infection in First Nations populations in Ontario: a retrospective matched cohort study. CMAJ Open. 2021 Jul-Sep; 9(3):E897-E906.
Score: 0.161
-
Hepatitis C virus infection in First Nations populations in Ontario from 2006 to 2014: a population-based retrospective cohort analysis. CMAJ Open. 2021 Jul-Sep; 9(3):E886-E896.
Score: 0.161
-
Cost-effectiveness analysis of sofosbuvir and velpatasvir in chronic hepatitis C patients with decompensated cirrhosis. J Viral Hepat. 2021 02; 28(2):260-267.
Score: 0.151
-
A model-based framework for chronic hepatitis C prevalence estimation. PLoS One. 2019; 14(11):e0225366.
Score: 0.141
-
Bridging Hepatitis C Care Gaps: A Modeling Approach for Achieving the WHO's Targets in Ontario, Canada. Viruses. 2024 07 31; 16(8).
Score: 0.049
-
Hepatitis C Attributable Healthcare Costs and Mortality among Immigrants: A Population-Based Matched Cohort Study. Can J Gastroenterol Hepatol. 2024; 2024:5573068.
Score: 0.047
-
Characterizing the cascade of care for hepatitis C virus infection among Status First Nations peoples in Ontario: a retrospective cohort study. CMAJ. 2023 04 11; 195(14):E499-E512.
Score: 0.045
-
The health impact of delaying direct-acting antiviral treatment for chronic hepatitis C: A decision-analytic approach. Liver Int. 2020 01; 40(1):51-59.
Score: 0.035